Tianjin Tianyao Pharmaceuticals(600488.SH) subsidiary received drug GMP compliance inspection results.

15:55 02/04/2026

Jinyao Pharmaceutical (600488.SH) announced that its subsidiary, Hubei Jinyao Pharmaceutical Co., Ltd. ("Hubei Jinyao"), recently received a "Notice of Hubei Province Drug GMP Compliance Inspection" (No. E GMP2026-90) issued by the Hubei Provincial Drug Administration. The inspection scope covers small volume injections/lincomycin phosphate injections (China Food and Drug Administration Approval No. H20065073).

Tianjin Tianyao Pharmaceuticals (600488.SH) announced that its subsidiary, Hubei Tianjin Tianyao Pharmaceuticals Co., Ltd. (referred to as "Hubei Jinyao"), recently received a "Notice of Hubei Drug GMP Compliance Inspection" (No. Hubei GMP2026-90) issued by the Hubei Provincial Drug Administration. The inspection scope includes small volume injections / lincomycin phosphate injections (national drug standard H20065073).

China Galaxy Securities: High oil prices fluctuate, focus on alternative routes for oil.

Sinolink: Collaborative computing included in national strategy, multi-industry resonance on the same frequency.

Energy crisis does not hinder the expansion ambition: Microsoft Corporation (MSFT.US) increases investment in Japan by $10 billion, joining forces with SoftBank and Sakura to build AI cloud infrastructure.

China Galaxy Securities: High oil prices fluctuate, focus on alternative routes for oil.

Sinolink: Collaborative computing included in national strategy, multi-industry resonance on the same frequency.